BALTIMORE, MD--(Marketwired - Jun 5, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, believes that the low level of toxicity in the Nuvilex Inc. (
The results of Nuvilex's oft-cited Phase II pancreatic cancer trial of 14 patients demonstrated that the patients' median survival rate doubled compared to historical control and results of the current gold standard used today, which is Gemzar®. Plus, the 1-year survival rate was triple that of control and double that of the standard Gemzar® therapy. Perhaps the most telling component of the trial was the fact that only one-third of the standard chemotherapy dosage was used, thereby measurably increasing the patient quality of life as compared to other therapies.
For example, according to the Gemzar.com website, the side effects of using the treatment for pancreatic cancer are many, with varying ranges of severity. On the mild side, nausea, diarrhea, fever and hair loss are common in anywhere from 3:10 to 7:10 of patients. In addition, 7 out of 10 patients suffered from anemia, low white blood cell count, and changes in their liver function tests.
In future tests, Nuvilex will likely use stand-alone Gemzar® therapy as a comparator. But, if early Nuvilex results are an indication, it is not just efficacy that could serve patients well, but if combined with an approved low toxicity due to the reduced chemotherapy dosage, clinicians and patients could seek out the treatment in droves.
A copy of this article as well as other articles and Nuvilex reports can be accessed by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (